太原地区404例女性HPV感染状况及基因分型统计分析

目的探讨太原地区女性人乳头瘤病毒(HPV)感染情况以及基因分型分布及特点。方法采用人乳头瘤病毒基因分型检测试剂盒(PCR技术及导流杂交技术)对太原地区404例女性进行21种HPV亚型分析。结果 404例检测者共检测到HPV阳性患者213例,阳性率为52.7%。21种HPV亚型(除HPV 42、43型外)均有检出,其中检出率较高的高危型有HPV 16(34.4%),HPV 58(13.4%),HPV 53(8.7%);检出率最高的低危型是HPV 6(2.2%)。阳性检出者中单一亚型感染占59.6%,多种亚型感染占40.4%;在多重感染中,伴随着合并感染的亚型数增加,比例逐渐下降。结论利用PCR技术和杂交技术检测女性HPV感染情况,对宫颈癌的早期诊断、预防及疗效观察具有重要的应用价值。     

安岳地区女性高危型HPV基因分型结果分析

目的 分析安岳地区女性高危型人乳头瘤病毒的感染以及各亚型的分布情况,为本地区宫颈癌防治及流行病学研究提供依据。方法 收集2016年1月~2017年12月年安岳地区自愿进行15种高危型HPV检测的女性宫颈脱落细胞标本2078例,应用实时荧光定量PCR进行包括16、18、31、33、35、39、45、51、52、53、56、58、59、66、68在内的15种HR-HPV检测,分析HR-HPV在人群中的总体和不同年龄段感染情况以及各亚型的分布特点。结果 2078例女性宫颈脱落细胞标本总阳性检出率为22.81%,其中单一感染占17.37%,混合感染占5.44%;在各年龄组中＜20岁组与＞60岁年龄组HR-HPV感染率最高,差异具有统计学意义（P＜0.05）;15种高危型中检出前五位的依次为:52型、16型、31型、53型、58型。结论 本地区女性人群的高危型HPV检出率较高,对本地区相关人群进行高危型HPV筛查非常必要。     

广州东部妇女宫颈人乳头瘤病毒16型感染及基因分析

目的 研究广州东部妇女中人乳头瘤病毒16型(HPV-16)宫颈感染分布,分析其早基因E6/E7的多态性,分析L1和E6基因定量与病程的关系.方法 通过导流杂交基因芯片技术检测宫颈脱落细胞的HPV-16感染;通过特异性扩增获取病毒早基因E6/E7序列,克隆测序并进行多态性分析;荧光定量PCR技术对E6基因和L1基因进行定量分析.结果 806例宫颈脱落细胞样本中HPV-16感染阳性36例(4.5%),其中18例(50.0%)宫颈细胞发生高度以上病变;7例(4例低度或以下病变,3例高度以上病变或浸润癌)阳性标本得到E6/g7序列有15个位点分别出现变异;高度病变组(A组,11例)与低度或以下病变组(B组,14例)的L1基因和E6基因定量数据对数值均有显著差异(P<0.05),但L1/E6比值差异无统计学意义(P=0.19).结论 本地区在17～62岁妇女中HPV-16感染阳性发生率约4.5%,50.0%发生高度以上宫颈病变,本研究显示病毒基因拷贝数与宫颈病变程度可能有关,L1/E6比值未能提示病毒整合的发生.     

2400例宫颈细胞脱落标本HPV筛查及荧光PCR基因分型和定量

目的建立快速、灵敏的HPV筛查方法及探讨HPV基因型与宫颈癌之间的关系.方法用细胞涂片法和传统PCR对2400例年龄在18～65岁的厦门郊区妇女进行筛查,对PCR阳性标本进一步进行荧光PCR基因分型和定量.结果 2400例宫颈脱落细胞普查中有宫颈原位癌4例、CIN(癌前病变)Ⅰ～Ⅲ级7例;PCR定性筛查这些标本中有84例阳性,阳性率为3.5%.对这84例阳性标本进行荧光基因分型和定量,发现13例HPV-16、18型阳性,其中HPV-16型阳性8例(占9.52%),HPV-18型阳性5例(5.95%),并且HPV-DNA拷贝数在3.6×103到5.6×107之间.在HPV-16、18型阳性的患者中宫颈原位癌3例(占75%)、CINⅠ-Ⅲ级5例(占71%).结论 HPV-16、18型与宫颈癌之间有高度相关性.     

子宫颈刮片中人乳头瘤病毒的基因分型

目的 确定不同型人乳头瘤病毒（ＨＰＶ）感染的自然历程以及其持续感染在子宫颈癌发展过程中的作用。方法 应用聚合酶链反应检测荷兰１５５名妇女子宫刮颈片中的ＨＰＶ ＤＮＡ，应用线样探针分析法（ＬｉＰＡ）进行，包括ＨＰＶ６，１１，１６，１８，３１，３３，３５，４０，４２，４３，４４，４５，５１，５２，５６和５８的基因分型。结果 １５５例妇女子宫颈片中ＨＰＶ ＤＮＡ检出率为６０％，其中在宫颈细胞学检查正常或     

实时荧光定量PCR法检测人乳头状瘤病毒的实验研究

目的 通过研究病变宫颈中人乳头状瘤病毒(HPV)16/18型的表达,探讨HPV16/18型病毒感染与宫颈病变发生发展之间的关系.方法 结合病理切片诊断,以免疫组化作对照.运用实时荧光定量PCR技术检测病变宫颈中HPV16/18型DNA拷贝数,以及HPV16/18型E7基因mRNA表达量.结果 慢性宫颈炎患者中HPV16/18型感染率低(7.4%).宫颈管上皮内瘤样变(CIN)组HPV16型感染率较高为69.6%,宫颈癌患者巾为72.7%.HPV16型DNA的拷贝数在宫颈上皮内瘤样变患者中与病理分级没有明显的相关性.但在宫颈癌患者中,病毒DNA的拷贝数明显升高,二者差异明显.CIN轻度(I)、中度(Ⅱ)、高度(Ⅲ)组和宫颈癌患者中,HPV16 E7基冈的表达率分别为0、37.5%、42.9%、63.6%.统计学分析表明,HPV16 E7 mRNA的拷贝数与病情呈明显的正相关性.结论 感染者中主要以HPV16型为主,HPV18型较少.宫颈癌患者中HPV16 DNA拷贝数明显高于CIN Ⅱ、Ⅲ组,HPV16型E7 mRNA在宫颈癌中表达率及表达量明显增加并与宫颈癌变呈正相关.实时荧光定量PCR适合临床宫颈病变病毒的筛查与检测.     

人乳头瘤病毒分型与宫颈病变关系的研究

目的探讨不同砸别人乳头瘤病毒（Human papilloma virus,HPV）感染与宫颈疾病发生发展的关系。方法应用核酸分子快速杂交基因分型技术,对375例宫颈病变患者（宫颈炎182例、CINI81例、CINⅡ68例、CINⅢ69例、宫颈癌15例）进行HPV感染基因型分型测定,同时进行宫颈细胞学检查。结果375例标本中HPV阳性检出率为35．2％,HPV在各类宫颈病变组的阳性枪出率分别为宫颈炎18．6％,CINI32．1％,CINⅡ57．3％,CINⅢ68．9％,宫颈癌86．7％,宫颈炎组和宫颈癌病变组HPV之间结果差异有统计学意义（x^2=105．0,P〈0．05）。HPV多重感染率为32．6％,其中最常见HPV感染亚型为HPV16。结论宫颈病变严重程度与感染HPV亚型的致病能力密切相关。HPV核酸分型检测对宫颈疾病诊断和治疗具有重要意义。     

许昌地区妇女宫颈人乳头瘤病毒感染型别分布特征分析

目的了解许昌地区妇女宫颈人乳头瘤病毒（HPV）感染的分布情况及高危因素,确定该地区的优势型别。方法采用PCR加导流杂交技术对3100例已婚妇女宫颈脱落细胞进行21种HPV基因检测,分析HPV感染高危因素及宫颈病变中HPV亚型感染分布特点。结论在检测的3100例妇女中感染总阳性率为18.8%,HPV感染阳性率排在前5位的亚型从高到低依次为HPV16、HPV58、HPV52、HPV11、HPV6,最低为亚型HPV43,占0.1%。HPV感染的高峰年龄为31～40岁,各年龄段HPV感染检出率差异在统计学上有显著意义（P〈0.05）。结论许昌地区HPV亚型感染分布以HPV16、HPV58、HPV52型为主,且存在明显的地域差异,HPV感染高发于中青年妇女。     

宫颈癌患者人乳头瘤病毒基因分型的研究

目的研究宫颈癌患者人乳头瘤病毒（HPV）感染及基因分型情况,为临床早期诊断和治疗提供参考。方法应用实时荧光定量聚合酶链反应（FQ-PCR）对655名来我院就诊女性患者进行HPV分型检测,共检测2种低危型和13种高危型。结果 655例患者中,HPV阳性率为31.45%（206/655）,其中低危型占67%（138/206）,HPV6为高发型,人群40岁以下为主;高危型占33%（68/206）,HPV6、11、16、18、52为高发型,人群以40岁以上为主;混合型阳性率为2.9%（19/655）。HPV6＋11,6＋18为高发型。结论本地HPV感染基因型以6、11、16、18、52、6＋11、6＋18为主,应针对此采取措施,防治相关疾病。     

一种新型基因芯片技术在人乳头瘤病毒(HPV)高通量基因分型检测的应用研究

目前应用比较多的采用反向点杂交/线性杂交方法的人乳头瘤病毒(HPV)基因分型检测方法,操作比较繁琐.该文通过设计针对29种HPV基因型的引物对和特异性探针,对HPV样品进行PCR扩增后,将反向引物生物素标记的PCR产物与固定在HPV基因芯片上的HPV DNA探针杂交、清洗和酶标显色,再对芯片进行图像分析转化为数字信号、确定HPV型别,建立HPV高通量基因分型方法(HPG).HPV基因芯片大小为0.36 cm2,每个芯片可在96孔板内的小孔中进行杂交和显色.与HCII方法检测的203例样本比较,对13种高危型检测的结果表明,HPG和HCII方法的一致性较好(kappa值0.663),HPG的分析灵敏度更高.显示了高通量快速检测的在大规模流行病调查、疫苗试验和常规诊断的临床应用前景.     

安阳市宫颈病变患者人乳头瘤病毒感染现状及基因分型分析

目的:分析安阳市宫颈病变患者人乳头瘤病毒（human papillomavirus,HPV）感染现状,并分析其基因型。方法:选取2018年6月至2020年12月在本院门诊就诊或住院治疗的宫颈病变患者372例,参照宫颈组织病理活检结果分为宫颈炎、宫颈上皮内瘤变（cervical intraepithelial neopl...     

Sensitivity of the cytologic diagnosis of cervical condyloma in comparison with HPV-DNA hybridization studies

The cytologic diagnosis of cervical condyloma is based on criteria developed over the last 10 years. It has now become possible to document the presence of human papilloma virus (HPV) DNA directly in cervical swabs by the highly sensitive technique of DNA filter hybridization in situ. The purpose of this article is to evaluate critically the empirically established cytologic criteria of condyloma by comparing them with HPV-DNA hybridization studies in the same material. The results of this study indicate that "classic" koilocytosis and dyskeratocytosis are not highly sensitive criteria for the presence of HPV infection, identifying only 15% of the HPV-DNA-positive cases correctly. In an attempt to improve the sensitivity of the cytologic diagnosis of HPV infections, a panel of nine "nonclassic" criteria was evaluated. The five most valuable signs were "mild koilocytosis," mild dyskeratocytosis," hyperchromatic nuclei, bi- and multinucleation, and cleared cytoplasm. Using these criteria in combination, statistically discriminant analysis could correctly identify 84% of the HPV-positive group.     

Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review

ObjectivesHuman papillomavirus (HPV) assays are increasingly used for primary cervical screening and HPV-vaccination-effect monitoring. We undertook a systematic literature review to determine the concordance in positive test results (i.e. detection of HPV infections) between Hybrid Capture 2 (HC2) and other assays.MethodsWe searched PubMed, Embase and Scopus for studies of primary screening with HC2 and one or more assays, with cross-tabulated testing results for the assays. Two authors applied inclusion criteria and three authors extracted data from included studies. For each inter-assay comparison, we calculated the concordance by comparing the number of concordant samples with the number of samples that tested positive on at least one assay.ResultsSixteen studies fulfilled inclusion criteria, comparing nine assays to HC2, and including 392 to 9451 patients each. The calculated concordance varied between 48% and 69% for HC2 and APTIMA, Cobas, Abbott RealTime, Cervista, GP5+/6+, CLART, BD HPV test, Amplicor and Linear Array, i.e. 31%–52% of all positive tests on any pair of compared assays were discordant. Although modest variation in the degree of concordance with HC2 was suggested for particular assays, the numbers of studies per assay were generally low. No pronounced systematic patterns were observed by study (e.g. liquid medium) or population characteristics.ConclusionsThe ten commercially available assays do not detect the same HPV infections. Even in the most favourable case, the two assays provided discordant test results in 31% of all detected infections.     

宫颈上皮内瘤样病变患者高危型HPV感染基因分型分析

目的了解宫颈上皮内瘤变患者的高危型HPV的感染及其分型和不同程度宫颈病变的主要感染型别情况。方法应用型特异PCR检测宫颈癌前病变的患者的主要高危型HPV-16、18、33、58的感染及其分型情况的相关性研究。结果在本研究宫颈上皮内瘤变患者98例中,4种高危型HPV的总阳性例数为73例,HPV总的感染率为74.5%,存在多重感染。其中HPV-16、18、33、58的总感染率分别为53.1%、38.7%、17.3%和30.6%。CIN的Ⅰ/Ⅱ/Ⅲ3组患者的4种高危型HPV的感染率分别为42.9%、61.1%和93.2%。结论主要高危型HPV在宫颈上皮内瘤变患者中感染的主要型别依次为HPV16、HPV18、HPV58、HPV33,主要为HPV16和HPV18型;不同程度CIN的高危型HPV的总感染率不同,随病变程度的加重而增加。     

Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China

To evaluate the effectiveness of Human papillomavirus16/18 infection referral to colposcopy in cervical cancer screening for women aged 25 years and older in Chinese northwest region Shaan'xi province. A total of 2224 women were diagnosed with primary high‐risk HPV infection by HPV‐DNA genotyping technology during August 2014 to August 2015. A total of 1916 cases referred for colposcopy with histological evidence were enrolled, including 1124 women with HPV16/18 genotype and 792 with other High‐risk human papillomavirus genotypes. A total of 1916 women aged 25 years and older with HR‐HPV positive were referred to colposcopy. The distribution of HPV16, HPV18, and other HR‐HPVs infection were 49.22%, 9.45%, and 41.33%, respectively. 71.56% had normal cervical histology, 7.05% had Cervical Intraepithelial Neoplasia1, 8.82% had CIN2, 7.25% had CIN3, and 5.32% had cervical cancer. The percentage of positivity of HPV16 and HPV18 was highly associated with the relative risk of cervical lesion. The sensitivity and specificity of HPV16/18 for detection of CIN2+ (CIN3+) was 82.68% (92.12%) and 47.87% (46.15%), respectively. The positive predictive value and negative predictive value of HPV16/18 for detection of CIN2+ (CIN3+) was 30.16% (19.75%) and 91.03% (97.60%), respectively. HPV16 and HVP18 are the most common genotypes in high grade cervical lesions in Shaan'xi province. Meanwhile, these two types play predominant roles in the progression of high grade cervical lesion. Primary HPV16/18 detection has high sensitivity and negative predictive value in cervical cancer screening and the strategy for women with HPV16 and HPV18 infection referral to colposcopy is efficient and feasible in northwestern region of China.     

Primary HPV-based cervical cancer screening in Europe: implementation status,challenges, and future plans

BackgroundCytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results.ObjectivesWe summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries.SourcesData were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites.ContentAs of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programmes. Implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries.ImplicationsHPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening.     

Comparison of human papillomavirus genotyping using commercial assays based on PCR and reverse hybridization methods

Different tests for human papillomavirus (HPV) screening are commercially available, detecting high‐risk oncogenic HPV types with a pool of genotype‐specific probes. However, it is necessary to establish reliable methods for the identification of individual genotypes. The purpose of this study was to compare three different commercial methods for HPV genotyping: INNO‐LiPA HPV Genotyping v2 (LiPA), Linear Arrays HPV Genotyping Test (LA) and Clinical Arrays Human Papillomavirus (CA). A total of 83 HPV DNA‐positive samples by hybrid capture method were genotyped (82, 78 and 81 by LiPA, LA and CA, respectively). Comparison analysis was limited to the HPV genotypes common to the three assays. There were concordant results (absolute agreement between assays) in 31 samples (39.7%) and compatible results (correspondence for some but not all genotypes) were found in 44 samples (56.4%). Only three samples (3.8%) were considered as discordant (did not show any similarity between the tests). Analyzing kappa values we have a very good agreement (>0.8) for HPV16 and HPV31 and good agreement (0.6–0.8) for HPV types 6, 18, 53 and 66 when all methods are compared. We conclude that all genotyping methods tested are highly comparable and suitable for clinical and epidemiological studies.     

表面等离子共振技术检测宫颈人乳头瘤病毒感染的临床研究

目的 研究表面等离子共振（SPR）技术在临床上检测宫颈人乳头瘤病毒（HPV）感染的情况.方法 运用SPR技术诊断502例宫颈HPV患者宫颈脱落细胞的HPV基因亚型,对比SPR技术和核酸分子快速导流杂交基因芯片（HybriMax）技术检测宫颈各级病变的HPV阳性率情况.结果 SPR技术检测出22种HPV基因亚型,单一感染106例,其中细胞学检查阳性47例（44.34％）;多重感染36例,其中细胞学检查阳性16例（44.44％）,2者间差异无统计学意义（P＞0.05）.106例单一感染患者中高危感染93例,其中细胞学检查阳性45例（48.39％）;中低危感染13例,其中细胞学检查阳性2例（15.38％）,2者间差异有统计学意义（P＜0.05）.SPR技术和HybriMax技术对比结果显示,2者检测宫颈各级病变的HPV阳性率结果间差异无统计学意义（P＞0.05）.结论 SPR技术用于检测HPV感染较为可靠,可和HybriMax技术作为临床检测的主要手段.